

Special Issue

Infectious Diseases: Antibodies and Vaccines

Message from the Guest Editors

Dear Colleagues, In the ongoing battle against human infectious diseases, antibodies and vaccines stand as powerful weapons, providing both preventive and therapeutic functions. This Special Issue serves as a comprehensive exploration of the latest advancements and insights in the field of immunology, focusing on the roles of antibodies and vaccines in combating infectious pathogens. This Special Issue presents a diverse array of research, ranging from fundamental discoveries in antibody biology to cutting-edge developments in vaccine design and delivery. Through a multidisciplinary lens, our topic delves into various aspects of immunity, including the generation of neutralizing antibodies, the mechanisms of vaccine-induced protection, and the challenges posed by emerging infectious threats. Key topics addressed in this Special Issue are as follows:

- Novel vaccine platforms and adjuvants for enhancing immune responses;
- Harnessing monoclonal antibodies for therapeutic intervention against infectious agents;
- Immune correlates of protection and their implications for vaccine efficacy;
- Strategies for enhancing vaccine uptake.

Guest Editors

Dr. Huibin Lv

Department of Biochemistry, University of Illinois at Urbana Champaign, Urbana, IL 61801, USA

Dr. Yupeng Feng

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/162461

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).